STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4155 by analyst upside · 2026-08-13
TXG
10x Genomics, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
-16.2%
implied upside to consensus target
Current Price $57.75
Consensus Target $48.38
Bull Target $60.0
Bear Target $40.0
Analysts Covering 13
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
4
Hold
8
Sell
0
52-Week Low $11.16
52-Week High $60.69
YTD Return +247.5%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E 284.0x
EPS (TTM) $-0.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $617M
Profit Margin -12.2%
52-WEEK RANGE
52-Week Low $11.16
52-Week High $60.69
Current Price $57.75
Bear Target $40.0
Bull Target $60.0
● Now $57.75 ● Target $48.38
TRADING DATA
Avg Volume 3.3M
YTD Return +247.5%
Analyst Count 13
Consensus Hold
Upside to Target -16.2%
Last Updated 2026-08-13

ANALYST SUMMARY

10x Genomics, Inc. (TXG) is currently trading at $57.75 with a Wall Street consensus price target of $48.38, which is 16.2% below the current price over the next 12 months. 13 analysts currently cover TXG, with a consensus rating of Hold - 38% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $40.0.

TXG operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 247.5% year-to-date and is currently trading near the upper end of its 52-week range of $11.16 – $60.69.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TXG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
JP Morgan - Reiterated
Neutral → Neutral 2026-05-12 43% win rate (7 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-20 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-04-20 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-04-14 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-04-07 Building track record
William Blair ↑ Upgrade
Market Perform → Outperform 2026-03-31 44% win rate (9 calls)
Stifel - Reiterated
Buy → Buy 2026-03-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
20/30
Consensus clarity
23/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →